July 20, 2018
Takeda Pharmaceutical and US biotech Ovid Therapeutics said on July 18 that they plan to start three new clinical studies for their investigational rare epilepsy treatment TAK-935/OV935, a first-in-class CH24H inhibitor, by the end of September. In January 2017, the...read more